Iksuda Therapeutics Showcases Encouraging Phase 1 Results for IKS014 in HER2+ Oesophageal Cancer
“Iksuda Therapeutics is set to highlight preliminary data from its Phase 1 trial of IKS014, a HER2-targeted antibody-drug conjugate, at the ASCO Gastrointestinal Cancers Symposium. The analysis reveals an 80% clinical benefit rate in pretreated patients with advanced HER2+ oesophageal cancer, underscoring potential advancements in treating this challenging malignancy.” Study Overview Iksuda Therapeutics, a UK-based … Read more